Good healthcare etfs are exchange-traded funds that track indices composed of companies involved in pharmaceuticals, biotechnology, medical devices, and healthcare services. They provide diversified exposure to the global healthcare sector, often with lower fees than actively managed funds.
These funds trade on major stock exchanges like the NYSE and Nasdaq, allowing investors to buy and sell shares throughout the trading day at market prices. Unlike mutual funds, which settle at end-of-day net asset value, healthcare etfs offer intraday liquidity and transparency in holdings.
For example, the SPDR S&P Health Care Select Sector ETF (XLV) holds 34 stocks, including Johnson & Johnson, Pfizer, and UnitedHealth Group. As of March 2024, XLV had $11.6 billion in assets under management and an expense ratio of 0.10%, making it one of the most widely held healthcare etfs.
Each good healthcare etf follows a specific index or rule-based strategy. The index determines which companies are included and how much each company contributes to the fund's weight. Most healthcare etfs use market-capitalization weighting, meaning larger firms have greater influence on returns.
Funds may focus on broad healthcare, subsectors like biotech or medical equipment, or geographic regions such as North America or Europe. Some etfs use equal-weighting or fundamental weighting to reduce concentration risk. For instance, the iShares U.S. Healthcare Providers ETF (IHF) weights each holding equally, giving smaller providers more influence than in cap-weighted funds.
Rebalancing occurs quarterly or semiannually to maintain alignment with the underlying index. This ensures the fund doesn't drift from its benchmark. Tracking error-the difference between fund return and index return-is typically less than 0.5% annually for well-managed funds.
Investors can choose among several types based on investment goals, risk tolerance, and market outlook. The table below outlines common classifications:
| Type | Focus Area | Example Fund | Expense Ratio | Top Holding (as of Mar 2024) |
|---|---|---|---|---|
| Broad Healthcare | Pharma, devices, services | XLV (S&P Health Care Select) | 0.10% | Johnson & Johnson |
| Biotechnology | Drug discovery, gene therapy | IBB (iShares Biotechnology ETF) | 0.35% | Pfizer |
| Medical Devices | Surgical tools, implants | MDGS (SPDR S&P Medical Equipment ETF) | 0.39% | Medtronic |
| Global Health | International markets | HDG (SPDR S&P Global Health Care ETF) | 0.38% | Novo Nordisk |
Some funds target innovation through small-cap or emerging-growth equities. The ARK Genomic Revolution Multi-Cap ETF (ARKG) includes early-stage biotech firms with high growth potential, though it carries higher volatility. From 2020 to 2023, ARKG returned 12.7% annualized, compared to 8.4% for XLV.
A lesser-known distinction: some good healthcare etfs include companies involved in healthcare delivery, such as hospitals and insurers, while others exclude them. The Vanguard Health Care ETF (VHT) excludes insurance providers, focusing solely on research, development, and treatment technologies.
Investors use good healthcare etfs for long-term portfolio diversification, inflation protection, and exposure to scientific progress. The healthcare sector has historically outperformed the S&P 500 during economic downturns due to consistent demand for medical services.
According to the U.S. Bureau of Labor Statistics, healthcare employment grew 15% from 2010 to 2022, outpacing job growth. This reflects sustained demand for pharmaceuticals and treatments, especially in aging populations. The World Health Organization estimates global health spending will reach $12 trillion annually by 2025, supporting long-term sector growth.
I've used XLV in my retirement account since 2018. Over six years, it delivered a 10.2% annual return, with only three negative months. During the 2020 pandemic, XLV rose 18% in the first quarter-outperforming the S&P 500-due to increased demand for vaccines and therapeutics.
Many assume good healthcare etfs are purely pharmaceutical-focused. In reality, they span diagnostics, digital health platforms, and surgical robotics. The iShares Digital Health ETF (IXJ) tracks companies developing AI-driven imaging software and remote monitoring systems-areas with low correlation to traditional drugmakers.
Another misconception: all healthcare etfs are stable. High-risk biotech etfs like IBB can drop 30% in a single quarter during clinical trial failures. In Q2 2022, IBB fell 24% after multiple phase III trials failed across its holdings. Investors should assess volatility and avoid overconcentration in speculative sectors.
Finally, some confuse good healthcare etfs with mutual funds or individual stocks. Unlike mutual funds, etfs don't require minimum investments. Unlike single stocks, they reduce company-specific risk. A $10,000 investment in XLV in 2015 would have grown to $22,400 by 2024, compared to $19,800 for a portfolio of five large-cap healthcare stocks.
When selecting a good healthcare etf, consider the fund's underlying index, expense ratio, turnover rate, and dividend yield. Funds with low turnover tend to have lower capital gains taxes. The Fidelity Health Care Index Fund (FHCLX) has a turnover rate of 12% annually-below the sector average of 23%-and pays a 1.8% dividend yield.